{"id":"folinic-acid-interferon-alpha","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Neuropsychiatric effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Folinic acid (leucovorin) acts as a cofactor that enhances cellular metabolism and may potentiate interferon-alpha's antiviral and anti-proliferative properties. Interferon-alpha is a cytokine that activates natural killer cells and macrophages to mount an immune response against malignant cells. The combination is designed to leverage synergistic immunomodulatory effects in cancer treatment.","oneSentence":"This combination uses folinic acid to enhance interferon-alpha's immunostimulatory effects, potentially improving anti-tumor immune response.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:24.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT04664010","phase":"NA","title":"Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19)","status":"COMPLETED","sponsor":"Xi'an International Medical Center Hospital","startDate":"2020-02-06","conditions":"COVID-19","enrollment":30},{"nctId":"NCT00002835","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1995-10-30","conditions":"Lymphoma","enrollment":116},{"nctId":"NCT00003063","phase":"PHASE3","title":"Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"1991-11","conditions":"Colorectal Cancer","enrollment":1050},{"nctId":"NCT00004897","phase":"PHASE2","title":"Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer","status":"TERMINATED","sponsor":"Northwestern University","startDate":"1999-10","conditions":"Esophageal Cancer","enrollment":""},{"nctId":"NCT00004231","phase":"PHASE2","title":"Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"1999-10","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00329368","phase":"PHASE1","title":"Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer","status":"COMPLETED","sponsor":"Endocyte","startDate":"2005-09","conditions":"Cancer","enrollment":13},{"nctId":"NCT00485563","phase":"PHASE2","title":"A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Endocyte","startDate":"2007-06","conditions":"Renal Cell Carcinoma","enrollment":12},{"nctId":"NCT01060501","phase":"PHASE3","title":"Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer","status":"COMPLETED","sponsor":"University of Ulm","startDate":"1992-07","conditions":"Rectal Cancer","enrollment":796}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Folinic Acid, interferon-alpha","genericName":"Folinic Acid, interferon-alpha","companyName":"University of Ulm","companyId":"university-of-ulm","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses folinic acid to enhance interferon-alpha's immunostimulatory effects, potentially improving anti-tumor immune response. Used for Metastatic renal cell carcinoma, Metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}